報價延遲最少15分鐘:2026/03/02 12:06 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
14.195 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.56/0.61
|
|
企業價值
1.93B
|
| 資產負債 |
|
每股賬面淨值
2.77
|
| 現金流量 |
|
現金流量率
0.06
|
| 損益表 |
|
收益
318.00K
|
|
每股收益
1.20
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases. |
